New hope for tough blood cancers: testing a Triple-Drug attack
NCT ID NCT05564650
Summary
This study is testing a new combination of three drugs—navitoclax, venetoclax, and decitabine—for patients with a high-risk type of blood and bone marrow cancer called myelodysplastic syndrome (MDS) that has come back or hasn't responded to standard treatments. The main goals are to find the safest dose and see if this triple-drug approach can help control the disease. The study involves taking oral pills and receiving intravenous infusions in repeating cycles, with close monitoring for side effects and treatment response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
Conditions
Explore the condition pages connected to this study.